Biotech | April 03, 2026
Nearly 40 industry groups unite to push for EU Biotech Act II
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Subscribe To Our Newsletter & Stay Updated
